1. Introduction {#s0005}
===============

Endometrial cancer is the most common gynecologic malignancy in the United States, with approximately 63,230 newly diagnosed cases and 11,350 associated deaths expected in 2018 ([@bb0080]). From 1987 to 2008, there was a 50% increase in the incidence of endometrial cancer, with an approximate 300% increase in the number of associated deaths ([@bb0015]; [@bb0060]). Although there are many chemotherapeutic and targeted therapies approved for ovarian, fallopian tube and primary peritoneal cancers, since the 1971 approval of megestrol acetate for the palliative treatment of advanced endometrial cancer, only pembrolizumab has been Food and Drug Administration approved for high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer. As a result, there has been an ever-growing focus on the development of novel therapies to treat advanced endometrial cancer.

Immune checkpoint inhibitors (i.e., monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 \[CTLA-4\], programmed cell death 1 \[PD-1\], and its ligand \[PD-L1\]) have revolutionized treatment in a myriad of malignancies previously associated with poor prognosis. Immunotherapy has been aggressively explored in endometrial cancer (NCT03367741, [NCT02982486](ctgov:NCT02982486){#ir0005}, [NCT03241745](ctgov:NCT03241745){#ir0010}, [NCT02899793](ctgov:NCT02899793){#ir0015}, [NCT03310567](ctgov:NCT03310567){#ir0020}, [NCT02630823](ctgov:NCT02630823){#ir0025}, and [NCT02501096](ctgov:NCT02501096){#ir0030}). Over the past several years, cases of myocarditis and fatal heart failure have been reported in patients with cancer treated with immune checkpoint inhibition (ICI), both as single agents and in combinations ([@bb0035]; [@bb0040]). Here, we present the first described case of acute immune-mediated myocarditis and myositis associated with durvalumab plus tremelimumab combination therapy. Of note, the patient was undergoing treatment for advanced endometrial cancer.

2. Case presentation {#s0010}
====================

A 75-year-old Caucasian woman presented with vaginal spotting. An endometrial biopsy revealed serous carcinoma. She underwent a robotically assisted radical hysterectomy, bilateral pelvic and aortic lymph node dissection, and omentectomy. Pathology revealed a stage IIIC2 serous carcinoma of the endometrium with one positive right aortic lymph node. DNA mismatch repair proteins were retained on immunohistochemistry. She received intravaginal radiation therapy followed by carboplatin area under the curve (AUC) 5 and paclitaxel.

After a 6-month remission, she was found to have newly metastatic disease, with bilateral pulmonary nodules, a hepatic lesion, and lymphadenopathy. She was enrolled on a randomized phase 2 trial comparing the PD-L1 inhibitor durvalumab alone versus durvalumab plus the CTLA-4 inhibitor tremelimumab for advanced endometrial cancer. She was randomized to the combination arm and received her first cycle of durvalumab 1500 mg flat dose and tremelimumab 75 mg flat dose. On Cycle 1 Day 1, she reported minimal side effects, only grade 1 skin pruritus.

Nearly 4 weeks after initiating immunotherapy, she presented with a 5-day history of difficulty ambulating due to neck weakness, imbalance, and progressive dyspnea on exertion. She was afebrile, with stable vital signs. She had no cardiac risk factors and denied any other cardiac symptoms. Her physical exam was normal; however, a chest radiograph demonstrated scattered interstitial opacities possibly due to pneumonitis and not an infectious or inflammatory process. Initial laboratory data were notable for newly developed transaminitis (aspartate transaminase \[AST\] 308/alanine transaminase \[ALT\] 252) and an elevated creatine phosphokinase (CPK) level to 5158 U/L (normal, \<140). Intravenous methylprednisolone at 1 mg/kg was started immediately for suspected pneumonitis and myositis. A CT of her chest ruled out pneumonitis, instead confirming bi-basilar consolidations and numerous metastases to lungs, liver, and bone.

Thirty-six hours later, her dyspnea had worsened, now requiring 6 L of nasal cannula (NC). She was found to be newly bradycardic (40 bpm), and an electrocardiogram (ECG) showed new complete heart block ([Fig. 1](#f0005){ref-type="fig"}A) with junctional escape rhythm, and at other times, accelerated idioventricular escape rhythm. She was transferred to the intensive care unit (ICU), where a transvenous pacer (TVP) was placed. Her troponin I, checked for the first time at this point, was elevated to 5 ng/mL (normal, \<0.02 ng/mL; [Fig. 2](#f0010){ref-type="fig"}). A bedside transthoracic echocardiogram (TTE) showed 54% left ventricular ejection fraction (EF), with regional areas of hypokinesis. Over the next 12 h, despite an escalated intravenous methylprednisolone dose to 10 mg/kg and the addition of mycophenolate mofetil 1000 mg oral twice daily, her troponin I rose to 6.7 ng/mL. She continued to alternate between intermittent intrinsic normal sinus rhythm at 80 bpm, and requiring pacing via TVP. The patient was then placed on 1000 mg (20 mg/kg) daily intravenous methylprednisolone (high dose) for presumed myocarditis secondary to ICI therapy, similar to the established treatment for acute rejection in orthotopic heart transplant patients. Emergent cardiac catheterization and endomyocardial biopsy were performed later that day and revealed non-obstructive coronary disease and lymphohistiocytic myocarditis ([Fig. 3](#f0015){ref-type="fig"}) with occasional eosinophils.Fig. 1(A) Electrocardiogram (ECG) with complete heart block showing atrial activity dissociated from ventricular activity. (B) ECG with resolution of heart block with synchronized atrial and ventricular activity.Fig. 1Fig. 2Time course of complete heart block occurrence, troponin elevation, and initiation of mycophenolate mofetil and high-dose steroids.CHB, complete heart block; TVP, transvenous pacemaker.Fig. 2Fig. 3Hematoxylin and eosin stain of right ventricular endomyocardial biopsy showing lymphohistiocytic infiltration with occasional eosinophils.Fig. 3

Twelve hours after the initiation of 1000 mg intravenous methylprednisolone, her troponin I levels began to drop, steadily declining over the subsequent weeks ([Fig. 2](#f0010){ref-type="fig"}). She required intermittent pacing for 2 days while receiving high-dose methylprednisolone, after which she returned to sinus rhythm ([Fig. 1](#f0005){ref-type="fig"}B). High-dose methylprednisolone was discontinued after 3 days, and she was started on 1.5 mg/kg prednisone, with a plan for tapering by 10 mg (0.2 mg/Kg) per week, and weekly troponin measurements for myocarditis recurrence surveillance. She was continued on mycophenolate 1000 mg twice daily, with a plan to discontinue the medication after completing her prednisone taper. She had a persistent 2 L NC oxygen requirement, attributed to her increased metastatic pulmonary cancer burden, which did not improve with diuresis. A TTE after pacing discontinuation demonstrated an abnormally low EF of 35%; she was started on enalapril for heart failure, which had to be discontinued due to low blood pressure. A repeat TTE 2 months after her presentation showed an improved EF of 59%. Despite these improvements, she still requires oxygen by NC and is unable to independently perform daily activities.

3. Discussion {#s0015}
=============

Immune checkpoint receptors on both T cells and non-immune--related cells such as those of the myocardium play a key role in the maintenance of self tolerance; their therapeutic blockade can alter immunological tolerance ([@bb0050]; [@bb0075]), resulting in autoimmune or inflammatory immune-mediated adverse events (AEs). Non-cardiac side effects of ICI are typically limited to grade ≤ 3 AEs treatable with low-dose steroids ([@bb0070]). Myocarditis associated with ICI, however, can be fulminant ([@bb0055]). More data are needed to establish the incidence of ICI-associated myocarditis. In a multi-center registry of ICI-associated myocarditis, the prevalence at one institution was 1%, with half of these patients experiencing major adverse cardiovascular events (MACEs) of grade 4 or 5 severity ([@bb0005]). In a Bristol-Myers Squibb safety database, 18 drug-related severe AEs of myocarditis (0.09% of the database) were noted ([@bb0025]; [@bb0020]), which is likely an underestimate, as myocarditis was not initially recognized as an AE of ICI. Combination therapy of an anti-CTLA-4 agent with either an anti-PD1 or anti-PD-L1 agent has been associated with an increased rate of myocarditis ([@bb0040]), as well as non-cardiac immune-mediated AEs, resulting in discontinuation of treatment in almost 40% of treated patients ([@bb0055]).

ICI is an important advancement in the treatment of metastatic malignancies, and clinicians should have the ability to recognize and manage the AEs associated with this treatment approach, as well as with strategies to help patients tolerate cardiac AEs ([@bb0040]). The median time to presentation of myocarditis is 34--65 days after initiation of treatment ([@bb0055]). Four of 5 cases of ICI-associated myocarditis occur within the first 3 months of starting therapy ([@bb0045]; [@bb0065]) and a troponin T of ≥1.5 ng/mL is associated with a four-fold increase of cardiovascular death, cardiogenic shock, cardiac arrest, and hemodynamically significant complete heart block ([@bb0010]). Although data are lacking, experience-based algorithms for myocarditis surveillance have proposed checking troponin with every infusion (if dosed every 3 weeks) or with every other infusion (if fortnightly dosed) for the first 3 months of treatment ([@bb0055]; [@bb0030]). TTE does not appear to be an effective surveillance tool, as more than half of ICI-associated myocarditis cases present with a normal EF ([@bb0055]). Patients with suspected ICI-associated myocarditis (i.e., presenting with symptoms of shortness of breath, chest pain, orthopnea, paroxysmal nocturnal dyspnea or fatigue) should have troponin measured and promptly referred to cardio-oncology or cardiology if warranted. Current registry data have relied upon cardiac magnetic resonance imaging or endomyocardial biopsy to establish a myocarditis diagnosis ([@bb0055]). In the event of hemodynamic instability or conduction abnormality, patients should be transferred to a cardiac ICU ([@bb0055]; [@bb0010]).

Recent data suggest ICI-associated myocarditis is amenable to treatment with immunosuppression ([@bb0055]). Higher mg/kg dosing of intravenous methylprednisolone is associated with a lower rate of major adverse cardiovascular events (2 mg/kg vs 0.8 mg/kg, *p* = 0.04 for non-MACE vs MACE, respectively). There was a non-significant trend towards less MACE when methylprednisolone is started promptly on admission for myocarditis (18 h vs 27 h, *p* = 0.12 for non-MACE vs MACE, respectively). Data on the use of other immunosuppressive agents such as mycophenolate, infliximab, and anti-thymoglobulin are lacking.

This is the first described case of durvalumab and tremelimumab--associated myocarditis and myositis. This AE occurred after the initial dose and progressed rapidly. Myocarditis was accompanied by other immune-related AEs and responded to high-dose steroids and mycophenolate. Left ventricular dysfunction was not the initial symptom, and cardiac symptoms were not prominent early on. Vigilance on the part of the treating oncologist and close monitoring for immune-related cardiac events is imperative, as the mortality associated with cardiac AEs is high. However, prompt initiation of high-dose intravenous methylprednisolone is associated with improved cardiac outcomes ([@bb0055]; [@bb0030]).

4. Conclusions {#s0020}
==============

Although myocarditis is a serious AE of ICI therapy, the cardiotoxicity is treatable with high-dose immunosuppression, as seen in our case report. ICI is an important advancement in cancer therapy, and this case report provides insight into the management of cardiac AEs associated with cancer therapy.
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